• Mashup Score: 1

    Epidemiological data may stimulate national cancer control programmes, pharmaceutical company interest and clinical trial participation

    Tweet Tweets with this article
    • #ESMOasiaweek21: How can quantifying the burden of #rarecancers in Asia improve pts outcomes? National #cancer control programmes, pharmaceutical company interest & facilitation of clinical trial participation may be stimulated by epidemiological data 👉 https://t.co/yHMiN1Dgzn https://t.co/ZjvjbWtn4F

  • Mashup Score: 0

    Biosimilars make certain medicines more affordable, but cost and availability drive the need to find ways to improve access

    Tweet Tweets with this article
    • #ESMOasiaweek21: Do #biosimilars improve access to #oncology medicines in #Asia? Biosimilars make certain medicines more affordable, but cost and availability drive the need to find ways to improve access 📑 https://t.co/RKm4EbjADM #ESMO-MCBS @VriesElisabeth https://t.co/PSXAaGWUfW

  • Mashup Score: 0

    This ESMO Webinar is part of the ESMO Asia Virtual Oncology Week 2021, which is freely available to all healthcare professionals working in Oncology.

    Tweet Tweets with this article
    • #GastricCancer webinar starts in a few hours📌Register for free to join this live discussion on the current paradigm in gastric/GEJ adenocarcinoma. Submit your questions to the experts! ⏰Today 12:30 CET; 19:30 SGT 📝https://t.co/ezopJ6m2jH Part of #ESMOasiaweek21 https://t.co/voC1ZVpbwB

  • Mashup Score: 1

    This ESMO Webinar is part of the ESMO Asia Virtual Oncology Week 2021, which is freely available to all healthcare professionals working in Oncology.

    Tweet Tweets with this article
    • Free registration - Discover the upcoming treatment strategies for pts w/ gastric/GEJ #cancer, & participate in this live, interactive webinar, part of #ESMOasiaweek21 📌Tomorrow 23 Nov 12:30 CET; 19:30 SGT 👉 https://t.co/0qq2sHVfqZ 👈 @HannekevanLaar1 #her2 #gastriccancer https://t.co/OoUICKLdYx

  • Mashup Score: 1

    Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in Asia

    Tweet Tweets with this article
    • #ESMOasiaweek21: Some practice-changing results in #breastcancer perceived differently in low-resourced countries. Cost, limited drug availability & lack of diagnostic testing facilities hurdles to adopting practice-changing recommendations https://t.co/I64EauDmve #bcsm https://t.co/59HsZY8orV

  • Mashup Score: 0

    In gastric cancer, effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines

    Tweet Tweets with this article
    • #ESMOasiaweek21: Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines ➡️ https://t.co/zOtTl04Q7L ESMO Webinar on #GastricCancer (free) ⏰ 23 Nov 12:30 CET; 19:30 SGT https://t.co/w3PHcgt3xJ https://t.co/PIxfnkM566

  • Mashup Score: 0
    Module - 2 year(s) ago

    Tweet Tweets with this article
    • How to efficiently run #clinicaltrials in Asian countries? W/ @TonyMok9, Eileen Poon & @DrJonLim, part of the Young Oncologist Lounge Discussions 📌 22 Nov 19:00 SGT (12:00 CET) 👉 Access the #ESMOasiaweek21 platform (free): https://t.co/wJ9H1ROWxq @TeresaSAmaral #ESMOYOC https://t.co/i16bOs7Tml

  • Mashup Score: 0

    The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines is presented at the ESMO Asia Virtual Oncology Week 2021

    Tweet Tweets with this article
    • #ESMOasiaweek21: #Genetics and availability of treatments influence the management of #headandneckcancer in Asia. The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines presented. ➡️ https://t.co/pTmy1Y6hEO #hncsm @EHNSnews @ESTRO_RT @Annals_Oncology https://t.co/1vhGdEs8vO